Abstract

Glioblastoma (GBM) is a disease that strikes without warning, often manifested by a single seizure or a few days of progressive headaches, yet evaluation with magnetic resonance imaging reveals a large mass that was likely present for months. Its stealth-like behavior belies the hallmark feature of this deadly cancer; it infiltrates normal brain diffusely, early in the disease course and over long distances, making it impossible to detect early or to cure surgically. The median survival time is 15 months with approximately 25% of patients alive at 2 years. The mainstay of treatment is external beam radiation in combination with the oral alkylating agent, temozolomide. The glioblastoma genome has been well characterized, yet no molecular targeted therapies have yet proven effective in the clinic. Improvements in outcome for this devastating disease will require a better understanding of the pathophysiology and the development of robust preclinical models for testing new therapies.

Original languageEnglish (US)
Title of host publicationRosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition
PublisherElsevier Inc.
Pages909-917
Number of pages9
ISBN (Print)9780124105294, 9780124105492
DOIs
StatePublished - Nov 13 2014

Fingerprint

Glioblastoma
temozolomide
Molecular Targeted Therapy
Alkylating Agents
Headache
Epilepsy
Magnetic Resonance Imaging
Genome
Radiation
Survival
Brain
Therapeutics
Neoplasms

Keywords

  • Glioblastoma
  • IDH
  • Infiltration
  • Metabolism
  • Mouse models

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Maher, E. A., & Bachoo, R. M. (2014). Glioblastoma. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition (pp. 909-917). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-410529-4.00078-4

Glioblastoma. / Maher, Elizabeth A.; Bachoo, Robert M.

Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. p. 909-917.

Research output: Chapter in Book/Report/Conference proceedingChapter

Maher, EA & Bachoo, RM 2014, Glioblastoma. in Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., pp. 909-917. https://doi.org/10.1016/B978-0-12-410529-4.00078-4
Maher EA, Bachoo RM. Glioblastoma. In Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc. 2014. p. 909-917 https://doi.org/10.1016/B978-0-12-410529-4.00078-4
Maher, Elizabeth A. ; Bachoo, Robert M. / Glioblastoma. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition. Elsevier Inc., 2014. pp. 909-917
@inbook{8f23f4140ca745768456e57f139114e5,
title = "Glioblastoma",
abstract = "Glioblastoma (GBM) is a disease that strikes without warning, often manifested by a single seizure or a few days of progressive headaches, yet evaluation with magnetic resonance imaging reveals a large mass that was likely present for months. Its stealth-like behavior belies the hallmark feature of this deadly cancer; it infiltrates normal brain diffusely, early in the disease course and over long distances, making it impossible to detect early or to cure surgically. The median survival time is 15 months with approximately 25{\%} of patients alive at 2 years. The mainstay of treatment is external beam radiation in combination with the oral alkylating agent, temozolomide. The glioblastoma genome has been well characterized, yet no molecular targeted therapies have yet proven effective in the clinic. Improvements in outcome for this devastating disease will require a better understanding of the pathophysiology and the development of robust preclinical models for testing new therapies.",
keywords = "Glioblastoma, IDH, Infiltration, Metabolism, Mouse models",
author = "Maher, {Elizabeth A.} and Bachoo, {Robert M.}",
year = "2014",
month = "11",
day = "13",
doi = "10.1016/B978-0-12-410529-4.00078-4",
language = "English (US)",
isbn = "9780124105294",
pages = "909--917",
booktitle = "Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Glioblastoma

AU - Maher, Elizabeth A.

AU - Bachoo, Robert M.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - Glioblastoma (GBM) is a disease that strikes without warning, often manifested by a single seizure or a few days of progressive headaches, yet evaluation with magnetic resonance imaging reveals a large mass that was likely present for months. Its stealth-like behavior belies the hallmark feature of this deadly cancer; it infiltrates normal brain diffusely, early in the disease course and over long distances, making it impossible to detect early or to cure surgically. The median survival time is 15 months with approximately 25% of patients alive at 2 years. The mainstay of treatment is external beam radiation in combination with the oral alkylating agent, temozolomide. The glioblastoma genome has been well characterized, yet no molecular targeted therapies have yet proven effective in the clinic. Improvements in outcome for this devastating disease will require a better understanding of the pathophysiology and the development of robust preclinical models for testing new therapies.

AB - Glioblastoma (GBM) is a disease that strikes without warning, often manifested by a single seizure or a few days of progressive headaches, yet evaluation with magnetic resonance imaging reveals a large mass that was likely present for months. Its stealth-like behavior belies the hallmark feature of this deadly cancer; it infiltrates normal brain diffusely, early in the disease course and over long distances, making it impossible to detect early or to cure surgically. The median survival time is 15 months with approximately 25% of patients alive at 2 years. The mainstay of treatment is external beam radiation in combination with the oral alkylating agent, temozolomide. The glioblastoma genome has been well characterized, yet no molecular targeted therapies have yet proven effective in the clinic. Improvements in outcome for this devastating disease will require a better understanding of the pathophysiology and the development of robust preclinical models for testing new therapies.

KW - Glioblastoma

KW - IDH

KW - Infiltration

KW - Metabolism

KW - Mouse models

UR - http://www.scopus.com/inward/record.url?scp=84943339899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943339899&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-410529-4.00078-4

DO - 10.1016/B978-0-12-410529-4.00078-4

M3 - Chapter

SN - 9780124105294

SN - 9780124105492

SP - 909

EP - 917

BT - Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease: Fifth Edition

PB - Elsevier Inc.

ER -